EOI: Consumer and Carer Perspectives Needed on Clozapine

April 13, 2017

Consumer and carer perspectives, for inclusion in an online learning module (Clozapine)

 

The East Metropolitan Health Service (EMHS) recently led a review into a small number of incidents related to patients taking clozapine (anti-psychotropic medication). While there was no evidence to suggest that clozapine directly caused any of the incidents investigated, the review did suggest the general medical care and monitoring of this patient group could be enhanced by the development of a suite of resources for clinicians to guide their care.

 
Clozapine is an effective antipsychotic medication for the management of treatment resistant schizophrenia in cases where patients are non-responsive, or suffer intolerable side effects, to at least two neuroleptic agents other than clozapine.

 
EMHS is seeking expressions of interest from consumers on clozapine and carers with lived experience supporting a person on clozapine, to participate in a relaxed group discussion.

 

During these discussions, consumers and carers will be asked questions relating to their experience with the monitoring requirements of clozapine, any side effects they may have experienced and the impact the drug has made on their life and mental health condition. The discussion will be recorded and these responses will be used as part of an online learning module that will emphasise the patient experience and patient voice.

 
The aim of the learning module is to improve clinician knowledge and understanding of the stringent blood and physical health monitoring requirements for people on clozapine, to continually check side effects and support the management of these side effects.

 
Participants would be asked to attend a relaxed group discussion at Royal Perth Hospital, for approximately 1-2 hours. We would ideally like to speak with 2-3 consumers and their carers, and consumers are most welcome to bring a support person if they feel they needed support throughout the discussion and enquiry process. Participants would be entitled to be reimbursed for their time in accordance with the Fees for WA Health Consumer Council of WA Representatives payment (approx. $30 per hour). Participants would need to be available on Thursday 27th April from approx. 9:30am-11:30am (to be confirmed).

 
Expressions of interest to participate in the above process would be appreciated by Thursday 20 April 2017. Please contact Marani Hutton via email: marani.hutton@health.wa.gov.au to lodge your expression of interest.

Become a member
  • (08) 9258 8911
  • admin@comhwa.org.au
  • PO Box 176 Cannington WA 6987 31 Manning Road Cannington WA 6987
  • 9am - 5pm